


ELuNIR™ CORONARY STENT SYSTEM

The BIONICS Study at 2 Years



KEY FEATURES OF THE ELuNIR™ CORONARY STENT SYSTEM*

- Novel metallic spring tip for superior deliverability
- Dual-pattern strut design offers:
 - Uniform drug distribution
 - Narrowest strut width (40 and 72 μm)
 - Lowest metal footprint (11%) on the market
- Elastomeric polymer that is designed for long-term integrity
- Elutes ridaforolimus, a high therapeutic index limus drug

*Medinol data on file

STUDY DESIGN



PATIENT CHARACTERISTICS

- Patients with symptomatic coronary artery disease, including non–ST-segment elevation myocardial infarction, chronic total occlusion, saphenous vein graft, multivessel disease, overlap, bifurcations, in-stent restenosis, and no limitation on lesion length
- The subgroup population included those with left main disease and severe calcification



DAVID E. KANDZARI, MD
PRINCIPAL INVESTIGATOR,
BIONICS STUDY

Overall, the favorable outcomes observed with the ELuNIR™ stent in a more complex patient and lesion population endorse the safety and efficacy of this stent in patients representative of those routinely encountered in clinical practice.

	ELuNIR™ (n = 958 patients, 1,275 lesions)	RESOLUTE INTEGRITY™ (n = 961 patients, 1,277 lesions)	P VALUE
Left main*	1.1%	0.4%	.04
Severe calcification	13.3%	10.5%	.03

*Safety and efficacy has not been established in all scenario use for left main. Refer to instructions for use supplied with this device and available on cordis.com for complete information.


PRIMARY ENDPOINT

Twelve-month target leisure failure (TLF), a composite of cardiac death, target vessel myocardial infarction (TV-MI), and ischemia-driven target lesion revascularization (ID-TLR).


OUTCOMES

TLF AT 12 MONTHS

The EluNIR™ stent demonstrated a low TLF rate (5.4%) at 12 months and achieved the study's primary endpoint of noninferiority.




TLF AT 24 MONTHS



STENT THROMBOSIS THROUGH 2 YEARS

The EluNIR™ stent demonstrated a low rate of 0.1% late/very late stent thrombosis through 2 years.



BIONICS clinical data: Presented by Dr. D. Kandzari, CRT 2018